Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Losing a Malpractice Case May Depend on Where You Live
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
The Role We Play in Addressing Racial Disparity in Dermatology
The Mainstream Patient: February 2
2 Clarke Drive Cranbury, NJ 08512